U.S. FDA Finds Manufacturing Lapses At Eli Lilly Plant

US inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters, Marisa Taylor and Maggie Fick reported for Reuters.

The deficiencies detected included problems in tracking the manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment, the inspection report shows. I Photo: Momoneymoproblemz Wikimedia Commons

The US Food and Drug Administration (FDA) inspection in July at Lilly's Branchburg, New Jersey, plant detected eight separate deficiencies.

They included problems in tracking the manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment, the inspection report shows.

The inspection report, obtained through a Freedom of Information Act (FOIA) request by Reuters, was partially redacted to remove the names of any products affected.

Lilly said in a statement to Reuters that the company had asked the FDA to allow for "additional flexibility" to manufacture migraine treatment Emgality on a different production line if needed in the future.

WEEKLY FEATURE : Jose Mari Chan And The Christmas Anthem